YOKNEAM, Israel, May 7, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences:
BNP 3rd Annual Aesthetics Day
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings
When: Monday, May 19, fireside chat at 11:00 am ET
A live webcast of the presentation can be accessed here.
Barclays West Coast Bus Trip
Presenters: Yair Malca, Chief Financial Officer
Format: In-person investor bus tour at InMode's North American headquarters
When: Thursday, May 29
Location: Irvine, CA
Jefferies Global Healthcare Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst and one-on-one meetings
When: Wednesday, June 4, fireside chat at 3:10 pm ET
Location: New York, NY
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.22 |
| Daily Change: | -0.08 -0.56 |
| Daily Volume: | 983,595 |
| Market Cap: | US$1.080B |
April 28, 2025 March 03, 2025 February 04, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
